Table 2.
FGFR1 amplification and clinicopathological features for NSCLC
| Patient characteristics | Included studies | Heterogeneity test
|
Meta-analysis
|
Outcomes
|
||
|---|---|---|---|---|---|---|
| I2 (%) | P-value | Model | OR (95% CI) | P-value | ||
| NSCLC | ||||||
| Sex (male vs female) | 12 | 16.3 | 0.284 | Fixed | 2.32 (1.71–3.14) | <0.001 |
| Age (≥60 years vs <60 years) | 2 | 0 | 0.454 | Fixed | 1.19 (0.51–2.75) | 0.687 |
| Smoking vs no smoking | 12 | 33.9 | 0.119 | Fixed | 3.84 (2.29–6.43) | <0.001 |
| Histology (SCC vs non-SCC) | 13 | 42.3 | 0.054 | Fixed | 3.60 (2.82–4.59) | <0.001 |
| Lymph-node metastasis (yes vs no) | 4 | 30.6 | 0.229 | Fixed | 1.20 (0.79–1.83) | 0.384 |
| Differentiation (good vs moderate or poor) | 5 | 54.9 | 0.064 | Random | 0.40 (0.11–1.41) | 0.154 |
| Tumor size (T3 + T4 vs T1 + T2) | 4 | 0 | 0.898 | Fixed | 1.53 (0.94–2.47) | 0.081 |
| Stage (III–IV vs I–II) | 8 | 0 | 0.965 | Fixed | 0.97 (0.73–1.29) | 0.853 |
| SCC only | ||||||
| Sex (male vs female) | 5 | 0 | 0.733 | Fixed | 2.35 (1.41–3.92) | 0.001 |
| Smoking vs no smoking | 5 | 61.7 | 0.034 | Random | 2.57 (0.56–11.76) | 0.225 |
| Lymph-node metastasis (yes vs no) | 2 | 27.5 | 0.252 | Fixed | 1.13 (0.70–1.83) | 0.632 |
| Differentiation (good vs moderate or poor) | 2 | 46.9 | 0.17 | Random | 0.91 (0.13–6.15) | 0.921 |
| Tumor size (T3 + T4 vs T1 + T2) | 2 | 0 | 0.406 | Fixed | 1.75 (0.93–3.27) | 0.079 |
| Stage (III–IV vs I–II) | 4 | 0 | 0.775 | Fixed | 0.87 (0.55–1.37) | 0.543 |
Abbreviations: NSCLC, non-small-cell lung cancer; OR, odds ratio; CI, confidence interval; SCC, squamous cell carcinoma.